What do you think about generic drugs products? Results from a survey
Ferrero-Cafiero, J.M, Gich, I, Morros, R, Vedia, C, Antonijoan, R.M
Published in Clinical therapeutics (01.08.2015)
Published in Clinical therapeutics (01.08.2015)
Get full text
Journal Article
339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer
Manso, L., Pernas, S., Margelí, M., Blanch, S., Adamo, B., Salvador Bofill, F.J., Moreno, D., González, X., Pascual, T., Ferrero-Cafiero, J.M., Perou, C.M., Prat, A., Oliveira, M.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
Pascual, T., Stover, D.G., Thuerigen, A., Perou, C.M., Ciruelos, E.M., Casas Fernandez Tejerina, A., Spears, P., Roux, E., Hu, H., Lu, Y-S., Tolaney, S.M., Partridge, A., Villacampa Javierre, G., Ferrero Cafiero, J.M., Carey, L., Prat, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
40TiP SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
Bellet, M., Morales Murillo, S., Gasol Cudos, A., Amillano, K., Chic, N., González-Farré, X., Villagrasa, P., Ferrero-Cafiero, J.M., Pascual, T., Prat, A., Lange, C., Saura Manich, C.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
Oliveira, M., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa Ortega, P., Martinez Saez, O., Salvador Bofill, F.J., Cruz Jurado, J., Luna Barrera, A.M., Arumi de Dios, M.A., Vidal Losada, M.J., Guerra, J.A., Pernas Simon, S., Villacampa Javierre, G., Gonzalez-farre, B., Sanfeliu Torres, E., Santhanagopal, A., Falato, C., Ferrero Cafiero, J.M., Pascual, T., Prat, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.
Published in Annals of oncology (01.08.2023)
Published in Annals of oncology (01.08.2023)
Get full text
Journal Article
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Prat, A., Falato, C., Pare Brunet, L., Martinez Saez, O., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa, P., Salvador Bofill, F.J., Cruz Jurado, J., Gonzalez-Farre, B., Sanfeliu Torres, E., Ciruelos, E.M., Espinosa-Bravo, M., Izarzugaza Peron, Y., Pernas Simon, S., Esker, S., Fan, P-D., Ferrero Cafiero, J.M., Pascual, T., Oliveira, M.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
2O ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis
Pascual, T., Oliveira, M., Ciruelos, E.M., Bellet Ezquerra, M., Saura, C., Gavila Gregori, J., Pernas Simon, S., Muñoz, M., Vidal, M.J., Margeli Vila, M., Cejalvo, J.M., González-Farré, B., Espinosa-Bravo, M., Ferrero-Cafiero, J.M., Villagrasa, P., Prat, A.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC)
Ciruelos, E.M., Pernas, S., Perelló, A., Lopez, A., Salvador Bofill, F.J., Cejalvo, J.M., Blancas, I., Ponce Lorenzo, J., Servitja, S., Perez, M., Cruz, J., Albacar, C., Escrivá-de-Romaní, S.I., Guerra, J.A., González-Santiago, S., Sanfeliu, E., Rodriguez, C., Tolosa, P., Ferrero-Cafiero, J.M., Prat, A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
LBA3 SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)
Oliveira, M., Ciruelos, E.M., Morales Murillo, S., Salvador Bofill, F.J., Quiroga Garcia, V., Gavilá-Gregori, J., Cortegoso Mosquera, A.S., Vega Alonso, E., Henao, F., Servitja Tormo, S., Tolosa Ortega, P., Villacampa Javierre, G., Salvador, F., Paes Dias, M., Ferrero-Cafiero, J.M., González Farre, X., Pascual, T., Saura Manich, C.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article
265TiP SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer
Ciruelos, E.M., Pascual, T., Vazquez, R. Villanueva, Cejalvo, J.M., Parraga, K. Amillano, Bofill, F.J. Salvador, López-Barajas, I. Blancas, Diez, A. Ferrando, Peron, Y. Izarzugaza, Puy, M. Borrell, Fernandez-Martinez, A., Javierre, G. Villacampa, Ferrero-Cafiero, J.M., Dias, M. Paes, Salvador, F., Oliveira, M.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
Brasó-Maristany, F., Oliveira, M., Ortega, P. Tolosa, Vila, M. Margeli, Jurado, J. Cruz, Bofill, F.J. Salvador, Cejalvo, J.M., Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Saez, O. Martinez, Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., Pascual, T., Prat, A.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
Oliveira, M., Pascual, T., Villacampa, G., Munoz, M., Martorell, A. Perello, Lopez, M.E. Perez, Parraga, K. Amillano, Farre, X. González, Vila, C. Martinez, Ortega, P. Tolosa, Puy, M. Borrell, Vila, M. Margeli, Cejalvo, J.M., Zheteyava, Y., Sternberg, D.W., Fan, P.D., Santhanagopal, A., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Prat, A.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article
124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial
Oliveira, M., Pascual, T., Ortega, P. Tolosa, Vila, M. Margeli, Cejalvo, J.M., Jurado, J. Cruz, Bofill, F.J. Salvador, Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Martínez-Sáez, O., Brasó-Maristany, F., Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., Prat, A.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article